Academic literature on the topic 'Combination drug therapies'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Combination drug therapies.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "Combination drug therapies"
Hoeller, Christoph. "The future of combination therapies in advanced melanoma." memo - Magazine of European Medical Oncology 13, no. 3 (August 14, 2020): 309–13. http://dx.doi.org/10.1007/s12254-020-00640-x.
Full textRideout, Todd C., Scott V. Harding, Christopher P. F. Marinangeli, and Peter J. H. Jones. "Combination drug–diet therapies for dyslipidemia." Translational Research 155, no. 5 (May 2010): 220–27. http://dx.doi.org/10.1016/j.trsl.2009.12.005.
Full textPlana, Deborah, Adam C. Palmer, and Peter K. Sorger. "Independent Drug Action in Combination Therapy: Implications for Precision Oncology." Cancer Discovery 12, no. 3 (March 1, 2022): 606–24. http://dx.doi.org/10.1158/2159-8290.cd-21-0212.
Full textWebster, Rachel M. "Combination therapies in oncology." Nature Reviews Drug Discovery 15, no. 2 (February 2016): 81–82. http://dx.doi.org/10.1038/nrd.2016.3.
Full textBlumer, Vanessa, and Muthiah Vaduganathan. "A rationale for dedicated trials of combination therapy in heart failure." European Heart Journal Supplements 24, Supplement_L (December 1, 2022): L49—L52. http://dx.doi.org/10.1093/eurheartjsupp/suac116.
Full textGilad, Yosi, Gary Gellerman, David M. Lonard, and Bert W. O’Malley. "Drug Combination in Cancer Treatment—From Cocktails to Conjugated Combinations." Cancers 13, no. 4 (February 7, 2021): 669. http://dx.doi.org/10.3390/cancers13040669.
Full textYordanova, Anna, and Hojjat Ahmadzadehfar. "Combination Therapies with PRRT." Pharmaceuticals 14, no. 10 (September 30, 2021): 1005. http://dx.doi.org/10.3390/ph14101005.
Full textAzam, Faruque, and Alexei Vazquez. "Trends in Phase II Trials for Cancer Therapies." Cancers 13, no. 2 (January 7, 2021): 178. http://dx.doi.org/10.3390/cancers13020178.
Full textPettus, Kevin, Samera Sharpe, and John R. Papp. "In VitroAssessment of Dual Drug Combinations To Inhibit Growth of Neisseria gonorrhoeae." Antimicrobial Agents and Chemotherapy 59, no. 4 (January 26, 2015): 2443–45. http://dx.doi.org/10.1128/aac.04127-14.
Full textHwangbo, Haeun, and Adam C. Palmer. "Abstract 2739: Defining and evaluating drug additivity in clinical trials of combination cancer therapy." Cancer Research 82, no. 12_Supplement (June 15, 2022): 2739. http://dx.doi.org/10.1158/1538-7445.am2022-2739.
Full textDissertations / Theses on the topic "Combination drug therapies"
Phee, Lynette. "Unorthodox antimicrobial combination therapies for the treatment of multi-drug resistant Gram-negative infections." Thesis, Queen Mary, University of London, 2018. http://qmro.qmul.ac.uk/xmlui/handle/123456789/44695.
Full textGupta, Seema. "Experimental pharmacodynamic and kinetic studies related to new combination therapies against falciparum malaria /." Stockholm : Karolinska institutet, 2007. http://diss.kib.ki.se/2007/978-91-7357-066-4/.
Full textNguyen, Tran Dang. "The effects of different deployment strategies of artemisinin combination therapies on slowing down the spread of antimalarial drug resistance : investigation with individual-based simulations." Thesis, Open University, 2016. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.700132.
Full textPace, Emily A. "Investigating combinatorial ligand addiction provides insights into rational drug combinations in cancer therapy." Thesis, Boston University, 2012. https://hdl.handle.net/2144/34647.
Full textPLEASE NOTE: Boston University Libraries did not receive an Authorization To Manage form for this thesis or dissertation. It is therefore not openly accessible, though it may be available by request. If you are the author or principal advisor of this work and would like to request open access for it, please contact us at open-help@bu.edu. Thank you.
Cancer, the second most common cause of death in the United States, is a collection of diseases caused by uncontrolled cell growth and metastasis. The main treatment for cancer is chemotherapy, which generally kills fast growing cells nonspecifically and has many side effects. A different type of cancer treatment, called targeted therapy, aims to avoid general toxicity by using drugs that block the activity of specific gene products, usually encoded by oncogenes, which have been shown to drive tumor growth. To date, targeted therapies, alone or in combination with chemotherapies, have mainly been successful in rare subsets of patients with tumors addicted to single oncogenes. This has created a rationale to mainly treat patients with an oncogene-addiction (such as those carrying mutated or overexpressed kinases) with targeted therapies like erlotinib and trastuzumab, which inhibit human epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2/ErbB2), respectively. Here, evidence is provided that targeted therapies are also effective in tumors that are dependent on multiple growth factors - a phenomenon that is called combinatorial ligand addiction. Specifically, it is shown that ligands that bind the EGFR family and the hepatocyte growth factor receptor (HGFR/MET) can activate protein kinase B (PKB/ AKT) across a broad set of cancer cell lines, suggesting that ligand signaling is redundant and widespread. It is also shown that ErbB ligands have distinct signaling dynamics and strengths, which provides a rationale for investigating each component of the ErbB signaling network. Using a systematic approach, we found that ErbB3 is an imp01tant therapeutic target even though it is not overexpressed and lacks kinase activity. Furthermore, it is shown that cell lines with and without known oncogene-addiction express autocrine ligands and have improved growth inhibition with drug combinations that include autocrine ligand-blocking antibodies. This research demonstrates that combinatorial ligand addiction creates a new rationale for therapeutic combinations to improve efficacy and prevent resistance in cancer cells that are treated with current targeted drugs.
2031-01-01
Peralta, Donna V. "Synthesis and Applications of Mutimodal Hybrid Albumin Nanoparticles for Chemotherapeutic Drug Delivery and Phototherml Therapy Platforms." ScholarWorks@UNO, 2014. http://scholarworks.uno.edu/td/1886.
Full textChen, Yun-Ti, and 陳筠媞. "A new combination therapies on hepatocellular carcinoma by computational omics and structure-based drug design on membrane proteins and alternative splicing proteins." Thesis, 2018. http://ndltd.ncl.edu.tw/handle/44dyds.
Full textBooks on the topic "Combination drug therapies"
L, Goldstein Allan, Garaci E, Institute for Advanced Studies in Immunology & Aging., and International Symposium on Combination Therapies (2nd : 1992 : Acireale, Italy), eds. Combination therapies 2: Biological response modifiers in the treatment of cancer and infectious diseases. New York: Plenum Press, 1993.
Find full textL, Goldstein Allan, Garaci E, Institute for Advanced Studies in Immunology & Aging., and International Symposium on Combination Therapies (1st : 1991 : Washington, D.C.), eds. Combination therapies: Biological response modifiers in the treatment of cancer and infectious diseases. New York: Plenum Press, 1992.
Find full textCombination Therapies: Biological Response Modifiers in the Treatment of Cancer and Infectious Diseases. Springer, 2012.
Find full textGoldstein, Allan L., and E. Garaci. Combination Therapies: Biological Response Modifiers in the Treatment of Cancer and Infectious Diseases. Springer, 2012.
Find full textGoldstein, Allan L., and E. Garaci. Combination Therapies: Biological Response Modifiers in the Treatment of Cancer and Infectious Diseases. Springer London, Limited, 2012.
Find full textSerpell, Mick G. Antineuropathic medication combination therapy. Edited by Paul Farquhar-Smith, Pierre Beaulieu, and Sian Jagger. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780198834359.003.0068.
Full textMbabazi, Johnson. Combination of Drug Therapies Is Better Than Exercise Alone in Controlling HbA1c Levels Type 2 Diabetes Patients. Independently Published, 2019.
Find full textGoldstein, Allan L., and E. Garaci. Combination Therapies 2: Biological Response Modifiers in the Treatment of Cancer and Infectious Diseases. Springer London, Limited, 2012.
Find full textCombination Therapies 2: Biological Response Modifiers in the Treatment of Cancer and Infectious Diseases. Springer, 2012.
Find full textSiebert, Stefan, Sengupta Raj, and Alexander Tsoukas. Non-pharmacological treatment of axial spondyloarthritis. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780198755296.003.0014.
Full textBook chapters on the topic "Combination drug therapies"
Naing, Aung, Gordon B. Mills, and Funda Meric-Bernstam. "Combination Therapies Targeting the PI3K/AKT/mTOR Pathways." In Cancer Drug Discovery and Development, 151–80. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-34211-5_6.
Full textDey, Nandini, Brian Leyland-Jones, and Pradip De. "HER2 Signaling Network in Advanced Breast Cancer: Opportunities for Combination Therapies." In Cancer Drug Discovery and Development, 231–61. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-34211-5_8.
Full textGiembycz, Mark A., and Robert Newton. "Harnessing the Clinical Efficacy of Phosphodiesterase 4 Inhibitors in Inflammatory Lung Diseases: Dual-Selective Phosphodiesterase Inhibitors and Novel Combination Therapies." In Phosphodiesterases as Drug Targets, 415–46. Berlin, Heidelberg: Springer Berlin Heidelberg, 2011. http://dx.doi.org/10.1007/978-3-642-17969-3_18.
Full textCheah, Phaik Yeong, Michael Parker, and Nicholas P. J. Day. "Ethics and Antimalarial Drug Resistance." In Ethics and Drug Resistance: Collective Responsibility for Global Public Health, 55–73. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-27874-8_4.
Full textPerno, C. F., A. Bergamini, G. Milanese, M. Capozzi, G. Zon, R. Calio, and G. Rocchi. "Cytokines Modulate HIV Replication and the Activity of Antiviral Drugs in Cells of Monocyte/Macrophage Lineage." In Combination Therapies, 167–76. Boston, MA: Springer US, 1992. http://dx.doi.org/10.1007/978-1-4615-3340-5_20.
Full textBakar, Nurzahidah, F. Merlin Franco, and Noor Hasharina Hassan. "The Intersection of Kedayan Folk Medicine and Traditional Ecological Calendar." In Case Studies in Biocultural Diversity from Southeast Asia, 105–24. Singapore: Springer Nature Singapore, 2022. http://dx.doi.org/10.1007/978-981-16-6719-0_5.
Full textSarin, Prem S., Allan Goldstein, S. Agrawal, and Paul Zamecnik. "Use of Drugs Targeted to Inhibit Different Stages of the HIV Life Cycle in the Treatment of AIDS." In Combination Therapies, 123–29. Boston, MA: Springer US, 1992. http://dx.doi.org/10.1007/978-1-4615-3340-5_15.
Full textHildebrand, Keith R. "Device-Enabled Drug Infusion Therapies." In Drug-Device Combinations For Chronic Diseases, 182–213. Hoboken, New Jersey: John Wiley & Sons, Inc., 2015. http://dx.doi.org/10.1002/9781119002956.ch07.
Full textDe Pauw, Ines, Carolien Boeckx, and An Wouters. "Mechanisms of Cetuximab Resistance and How to Overcome It." In Critical Issues in Head and Neck Oncology, 21–51. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-63234-2_3.
Full textSturrock, R. D. "The Use of DMARDs and Combination Therapies." In Side Effects of Anti-Inflammatory Drugs IV, 333. Dordrecht: Springer Netherlands, 1997. http://dx.doi.org/10.1007/978-94-011-5394-2_40.
Full textConference papers on the topic "Combination drug therapies"
Reuveni, Hadas, Lana Kuperschmidt, Shani Carmi, Neta Moskovitz, Salomon Stemmer, and Izhak Haviv. "Abstract 4980: Rational design of combination therapies and block of acquired targeted drug resistance." In Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.am2015-4980.
Full textBrubaker, Doug, Svenson Elena, Kai Smith, Maya Monroe, Christopher Ryu, Mark R. Chance, Goutham Narla, and Gurkan Bebek. "Abstract PR04: Cancer drug response networks built for comparative cancer pharmacogenomics identifies combination therapies for repositioning." In Abstracts: AACR Special Conference: Translation of the Cancer Genome; February 7-9, 2015; San Francisco, CA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.transcagen-pr04.
Full textBrubaker, Douglas, Elena Svenson, Smith Kai, Maya Monroe, Christopher Ryu, Goutham Narla, Mark R. Chance, and Gurkan Bebek. "Abstract B1-43: Cancer drug response networks built for comparative cancer pharmacogenomics identifies combination therapies for repositioning." In Abstracts: AACR Special Conference: Computational and Systems Biology of Cancer; February 8-11, 2015; San Francisco, CA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.compsysbio-b1-43.
Full textChen, Xintong, Gustavo Stolovitzky, and Bojan Losic. "Abstract 790: Coupled dynamics of drug synergy, gene expression, and alternative splicing in combination therapies in breast cancer." In Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.am2016-790.
Full textZoergiebel, Johanna, Abir Kundu, Johannes Braegelmann, Wanda Shen, Mohamed El Dinali, Ravi Salgia, and Tanguy Seiwert. "Abstract A165: Determining drug inhibition profiles and opportunities for synergistic combination therapies in head and neck cancer cell lines." In Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics--Nov 15-19, 2009; Boston, MA. American Association for Cancer Research, 2009. http://dx.doi.org/10.1158/1535-7163.targ-09-a165.
Full textCapaldo, Brian J., Devin G. Roller, Mark Axelrod, Alex Koeppel, Michael J. Weber, Aaron Mackey, Dan Gioeli, and Stefan Bekiranov. "Abstract 4166: Integrated molecular profiling of melanoma cell lines reveals genotype-drug phenotype associations giving insight on development of combination therapies." In Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA. American Association for Cancer Research, 2014. http://dx.doi.org/10.1158/1538-7445.am2014-4166.
Full textLing, Alexander, and R. Stephanie Huang. "Abstract 5097: Clinical trial outcomes for drug combination therapies can be predicted by modeling independent action using cancer cell line screens." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-5097.
Full textLing, Alexander, and R. Stephanie Huang. "Abstract 5097: Clinical trial outcomes for drug combination therapies can be predicted by modeling independent action using cancer cell line screens." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.am2019-5097.
Full textFuchss, Thomas, Ulrich Graedler, Kai Schiemann, Daniel Kuhn, Holger Kubas, Heike Dahmen, Astrid Zimmermann, Frank Zenke, and Andree Blaukat. "Abstract 3500: Highly potent and selective ATM kinase inhibitor M4076: A clinical candidate drug with strong anti-tumor activity in combination therapies." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.am2019-3500.
Full textFuchss, Thomas, Ulrich Graedler, Kai Schiemann, Daniel Kuhn, Holger Kubas, Heike Dahmen, Astrid Zimmermann, Frank Zenke, and Andree Blaukat. "Abstract 3500: Highly potent and selective ATM kinase inhibitor M4076: A clinical candidate drug with strong anti-tumor activity in combination therapies." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-3500.
Full textReports on the topic "Combination drug therapies"
Gupta, Aditya, Tong Wang, Shruthi Ravi, Mesbah Talukder, Jessie Carviel, and Mary Bamimore. Relative efficacy of microneedling in the treatment of pattern hair loss: a protocol for a systematic review with network meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, September 2022. http://dx.doi.org/10.37766/inplasy2022.9.0042.
Full textWANG, Xuesong, Xuliang SHI, Jing LV, Juncha ZHANG, Yongli HUO, Guang ZUO, Guangtong LU, Cunzhi LIU, and Yanfen SHE. Acupuncture and Related Therapies for anxiety and depression in Diarrhoea-Predominant Irritable Bowel Syndrome(IBS-D): A Network Meta-Analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, March 2022. http://dx.doi.org/10.37766/inplasy2022.3.0162.
Full textHalker Singh, Rashmi B., Juliana H. VanderPluym, Allison S. Morrow, Meritxell Urtecho, Tarek Nayfeh, Victor D. Torres Roldan, Magdoleen H. Farah, et al. Acute Treatments for Episodic Migraine. Agency for Healthcare Research and Quality (AHRQ), December 2020. http://dx.doi.org/10.23970/ahrqepccer239.
Full text